Scarica l'app Stockscreener
112.65
0.19%
-0.22
Dopo l'orario di chiusura:
112.65
Precedente Chiudi:
$112.87
Aprire:
$113.2
Volume 24 ore:
347.42K
Relative Volume:
0.37
Capitalizzazione di mercato:
$6.82B
Reddito:
$3.99B
Utile/perdita netta:
$463.16M
Rapporto P/E:
15.87
EPS:
7.1
Flusso di cassa netto:
$1.10B
1 W Prestazione:
+1.09%
1M Prestazione:
+4.78%
6M Prestazione:
-7.23%
1 anno Prestazione:
+3.34%
Intervallo 1D:
$111.88
$113.96
Intervallo di 1 settimana:
$111.13
$116.77
Portata 52W:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
112.65 | 6.74B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Is Jazz Pharmaceuticals plc a good long term investmentAccelerated wealth expansion - Autocar Professional
What drives Jazz Pharmaceuticals plc stock priceTremendous growth opportunities - Autocar Professional
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E - simplywall.st
Jazz Pharmaceuticals plc Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
What analysts say about Jazz Pharmaceuticals plc stockFree Predictions - PrintWeekIndia
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire Inc.
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference - MSN
Jazz Pharmaceuticals Stock Offers Buying Opportunity After Slump, Deutsche Bank Says - MarketScreener
Deutsche Bank initiates Jazz Pharmaceuticals stock with Buy rating By Investing.com - Investing.com Nigeria
Deutsche Bank Initiates Jazz Pharmaceuticals at Buy With $152 Price Target - MarketScreener
What makes Jazz Pharmaceuticals plc stock price move sharplyFree Capital Allocation Plans - beatles.ru
Ireland: Renee Gala elected CEO at Jazz Pharma - Investors in Healthcare
Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update - BioPharma Dive
Jazz Pharmaceuticals Appoints Renee Gala as New CEO - The Globe and Mail
Jazz Pharmaceuticals names Renee Gala as next CEO By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals names Renee Gala as next CEO - Investing.com Australia
1 Profitable Stock with Solid Fundamentals and 2 to Brush Off - Yahoo Finance
Jazz Looks To Block Avadel From Asking For Sleep Drug OK - Law360
Avadel Pharmaceuticals Receives Unanimous Appeals Court Affirmation for LUMRYZ FDA Approval - Insider Monkey
Jazz Pharmaceuticals Names Renee Gala as President & CEO - Contract Pharma
Jazz Pharmaceuticals names Renee Gala as president and CEO - MarketScreener
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer - PR Newswire
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results - MSN
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor (NASDAQ:JAZZ) - Seeking Alpha
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Jazz Pharmaceuticals’ Ziihera Receives Conditional European Approval for Advanced Biliary Tract Cancer - Yahoo Finance
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer - Yahoo Finance
Jazz Pharmaceuticals Receives European Commission Marketing Auth - GuruFocus
Breakthrough: EU Approves First Targeted Therapy for Aggressive Bile Duct Cancer with 41% Response Rate - Stock Titan
ASL pushes for board shakeup at Avadel over handling of sleep drug rollout - Reuters
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
FDA Approvals and Clinical Trials Impacting Narcolepsy - openPR.com
Autistic Disorder Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Biosciences - Barchart.com
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):